#今日行业热点#

①The New England Journal of Medicine：Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

NEJM首次发表中国创新药试验——泽布替尼和伊布替尼治疗复发或难治性慢性淋巴细胞白血病的比较

DOI: 10.1056/NEJMoa2211582

②Nature Reviews Immunology：The role of platelets in immune-mediated inflammatory diseases

血小板在免疫介导的炎症性疾病（IMIDs）中的作用

DOI :10.1038/s41577-023-00834-4

③Arthritis & Rheumatology：Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist that Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases

增强型双APRIL/BAFF拮抗剂Povetacicept可调节B淋巴细胞和致病性自身抗体，用于治疗狼疮和其他B细胞相关自身免疫疾病

DOI :10.1002/art.42462

④Science：Low protease activity in B cell follicles promotes retention of intact antigens after immunization

B细胞滤泡的低蛋白酶活性促进免疫后完整抗原的保留

DOI :10.1126/science.abn8934

⑤Cell Metabolism：Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates

活性平衡的GLP-1/GDF15双激动剂降低小鼠和非人类灵长类动物的体重和代谢障碍

DOI :10.1016/j.cmet.2023.01.001

⑥Allergy：Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice

人源单克隆抗体靶向Ara h 2预防花生诱导的小鼠过敏反应

DOI :10.1111/all.15659

⑦首个针对BTK抗性癌症——礼来非共价选择性布鲁顿氏激酶（BTK）抑制剂获FDA加速批准

⑧歌礼制药宣布口服病毒聚合酶抑制剂ASC10猴痘适应症新药临床试验申请获得中国国家药监局批准

⑨对美国主流变异株无效！阿斯利康新冠中和抗体紧急使用授权被FDA撤回

⑩靶向B细胞成熟抗原（BCMA）的CAR-T疗法Carvykti可显著改善复发/难治性多发性骨髓瘤（RRMM）成人患者的无进展生存期（PFS）

科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！